MYMD - MyMD Pharmaceuticals, Inc. Stock Price, Fair Value and News

2.35USD+0.16 (+7.31%)Delayed

Market Summary

USD2.35+0.16

Delayed

7.31%

MYMD Stock Price

View Fullscreen

MYMD RSI Chart

MYMD Valuation

Market Cap

5.4M

Price/Earnings (Trailing)

-0.4

Price/Sales (Trailing)

3.09

EV/EBITDA

-0.42

Price/Free Cashflow

-0.5

MYMD Price/Sales (Trailing)

MYMD Profitability

EBT Margin

-779.20%

Return on Equity

-135.75%

Return on Assets

-93.08%

Free Cashflow Yield

-201.39%

MYMD Fundamentals

MYMD Revenue

Revenue (TTM)

1.6M

MYMD Earnings

Earnings (TTM)

-13.5M

Earnings Growth (Yr)

-627.77%

Earnings Growth (Qtr)

-365.48%

Breaking Down MYMD Revenue

Last 7 days

-6%

Last 30 days

4.4%

Last 90 days

-25.4%

Trailing 12 Months

-96.3%

How does MYMD drawdown profile look like?

MYMD Financial Health

Current Ratio

0.62

MYMD Investor Care

Shares Dilution (1Y)

74.80%

Diluted EPS (TTM)

-9.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	2.0M	1.9M	1.8M	1.6M
2018	3.0M	2.4M	2.3M	1.7M
2017	3.1M	3.2M	3.3M	3.4M
2016	1.2M	2.1M	0	3.0M
2015	4.4M	3.0M	1.7M	305.6K
2014	2.8M	2.5M	2.7M	4.7M
2013	0	0	0	3.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MyMD Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 24, 2023	rivard paul	bought	166,500	1.11	150,000	chief legal officer
Aug 17, 2023	rivard paul	bought	28,080	1.1232	25,000	chief legal officer
Dec 08, 2022	rivard paul	bought	15,300	1.53	10,000	evp of operations, gc
Nov 26, 2021	silverman joshua	bought	37,771	7.5543	5,000	-
Nov 24, 2021	silverman joshua	bought	65,586	6.55862	10,000	-
Nov 23, 2021	rivard paul	bought	90,450	6.03	15,000	evp of operations, gc
Apr 16, 2021	schroeder robert c	acquired	-	-	43,930	-
Apr 16, 2021	schroeder robert c	sold (taxes)	-72,588	4.94	-14,694	-
Apr 16, 2021	chapman christopher c jr	acquired	-	-	96,475	president, chief med. officer
Apr 16, 2021	silverman joshua	sold (taxes)	-189,326	4.94	-38,325	-

Which funds bought or sold MYMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-14,932	-	-%
May 16, 2024	Ancora Advisors LLC	sold off	-100	-698	-	-%
May 16, 2024	Ancora Advisors LLC	new	-	215	215	-%
May 15, 2024	STATE STREET CORP	sold off	-100	-31,109	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-2,806	-	-%
May 15, 2024	MORGAN STANLEY	new	-	535	535	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-15.00	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	2.00	2.00	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-16,069	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%

Are Funds Buying or Selling MYMD?

Are funds buying MYMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MYMD

No. of Funds

Unveiling MyMD Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	iroquois capital management, llc	4.99%	187,421	SC 13G/A
Feb 14, 2024	global x management co llc	6.11%	3,108,473	SC 13G
Feb 14, 2023	iroquois capital management, llc	2.85%	31,184	SC 13G/A
Sep 08, 2022	duffey samuel s	5.86%	2,241,812	SC 13D
Feb 23, 2022	iroquois capital management, llc	3.66%	260,366	SC 13G/A
Feb 11, 2022	intracoastal capital, llc	1.0%	364,963	SC 13G/A

Recent SEC filings of MyMD Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	3	Insider Trading
May 15, 2024	10-Q	Quarterly Report
Apr 18, 2024	8-K	Current Report
Apr 08, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 26, 2024	8-K/A	Current Report
Mar 07, 2024	8-K	Current Report
Mar 05, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to MyMD Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

MyMD Pharmaceuticals, Inc. News

Latest updates

MyMD Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-	-	-	-	-	-	-	-	-	-	-	43,453	55,497	67,541	79,585	420,812	464,513	612,123	279,405	557,089	526,601	302,475
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-379,057	190,644	-267,390	135,302	244,649	366,186	-182,101	80,636	223,775	4,975
S&GA Expenses	-100.0%	-	1,240,292	987,987	1,224,031	1,554,244	1,346,763	1,395,112	2,386,200	1,428,795	1,540,392	1,078,163	484,921	6,250	-69,446	6,163	14,139	149,841	448,053	364,641	469,469	500,152
R&D Expenses	-59.5%	1,198,938	2,960,599	770,430	2,470,481	1,803,232	2,163,968	2,629,741	739,997	2,979,408	1,661,265	1,350,976	1,916,161	2,483,057	3,420,937	57,502	60,909	88,391	203,292	160,867	259,124	-
EBITDA Margin	-208.7%	-7.77	-2.52	-7.95	-9.61	-9.12	-10.25	-19.42	-18.76	-17.84	-16.43	-5.65	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-314.6%	-9,800,041	-2,363,559	-1,511,732	-3,745,518	-3,693,741	-3,636,043	-4,122,033	-3,239,724	-5,467,281	-18,092,336	-3,089,703	-1,094,909	-3,534,466	-763,396	-820,844	-794,891	-916,958	-3,837,640	-3,083,950	-2,067,453	-
EBT Margin	-207.2%	-7.79	-2.54	-7.98	-9.64	-9.32	-10.44	-19.61	-18.95	-18.73	-17.32	-6.54	-	-	-	-	-	-	-	-	-	-
Net Income	-365.5%	-11,001,908	-2,363,559	-1,511,732	-3,745,518	-3,693,741	-3,636,043	-4,122,034	-3,239,724	-5,467,281	-18,092,336	-3,089,704	-1,094,909	-981,949	-1,339,374	-837,026	-794,891	-916,958	-3,837,640	-3,083,950	-2,067,453	-
Net Income Margin	-237.3%	-8.55	-2.54	-7.98	-9.64	-9.32	-10.44	-19.61	-18.95	-19.54	-18.13	-7.35	-	-	-	-	-	-	-	-	-	-
Free Cashflow	1.1%	-1,912,041	-1,932,630	-3,971,642	-2,248,404	-15,955,909	8,300,427	-2,366,182	-4,812,467	-6,445,512	-6,753,314	-1,505,182	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-18.9%	14,494	17,862	21,826	25,249	28,409	17,540	20,231	19,161	22,204	24,813	28,010	34,448	35,798	29,761	23,725	18,678	9,122	10,885	4,971	5,932	7,042
Current Assets	-57.7%	2,460	5,816	9,736	13,143	16,287	5,402	8,077	6,992	10,072	12,665	15,948	22,375	34,298	150	23,566	18,478	8,296	10,311	4,315	5,250	5,962
Cash Equivalents	-91.6%	226	2,681	298	94.00	189	749	310	1,115	1,189	556	1,375	2,127	569	148	16,190	11,447	812	517	363	248	276
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	193	199	412	544	601
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00	5.00	27.00	11.00	59.00	68.00	78.00
Goodwill	0%	10,499	10,499	10,499	10,499	10,499	10,499	10,499	10,499	10,499	10,499	10,499	10,499	-	-	-	-	-	-	-	-	-
Liabilities	-16.4%	4,253	5,089	5,716	13,747	14,402	2,845	1,904	3,043	2,581	1,166	2,118	3,374	2,374	5,934	2,556	2,706	2,304	1,530	1,373	1,618	2,076
Current Liabilities	-20.3%	3,973	4,988	5,696	2,429	1,626	2,769	1,781	2,903	2,467	1,040	2,092	3,348	2,374	2,348	2,556	2,706	2,180	1,530	1,373	-	-
Shareholder's Equity	-19.7%	9,938	12,370	15,501	10,742	13,094	14,695	18,327	16,118	19,622	23,647	25,892	31,074	33,424	34,579	21,169	15,972	6,817	9,355	3,598	4,314	4,966
Retained Earnings	-10.8%	-112,978	-101,977	-97,085	-99,970	-95,428	-93,758	-90,013	-86,319	-82,683	-78,561	-75,321	-69,854	-138,646	-48,672	-133,876	-126,749	-123,121	-119,583	-118,243	-117,406	-116,611
Additional Paid-In Capital	7.5%	122,770	114,200	-	-	-	108,308	-	-	-	-	-	-	43,411	43,411	-	-	-	36,848	-	-	-
Shares Outstanding	6.9%	2,158	2,019	1,567	1,401	1,316	1,316	1,283	1,274	1,271	1,256	1,135	1,197	952	-	-	-	-	-	-	-	-
Float	-	-	-	-	63,000	-	-	-	70,298	-	-	-	21,254	-	-	-	21,254	-	-	-	5,835	-

Cashflow (Last 12 Months)

(In )

Cashflow (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	1.1%	-1,912,041	-1,932,630	-3,156,478	-3,919,875	-3,971,642	-2,248,404	-15,955,909	8,300,427	-2,366,182	-4,812,467	-6,445,512	-6,753,314	-1,505,182	-1,248,182	-1,285,277	-163,104	-1,966,983	-501,705	-962,226	-861,617	-748,735
Share Based Compensation	-30.3%	517,365	742,156	595,576	1,677,271	-	162,028	352,417	132,246	-	-	15,036,051	15,036,051	979,758	567,300	272,700	6,016	1,302	3,335,385	-	-	-
Cashflow From Investing	-87.7%	732,024	5,934,192	3,360,973	3,825,150	-11,274,589	2,687,568	-2,267,857	3,494,014	2,999,438	2,998,448	5,498,286	26,919,533	-15,565,642	-10,967,502	-21,334	-30,534	2,261,901	-6,309,838	1,077,081	469,628	822,502
Cashflow From Financing	21.2%	-1,275,338	-1,618,870	-	-	14,685,689	-	-	-	-	994,972	194,868	-2,910,489	1,794,182	1,349,482	1,274,500	2,053,272	77.00	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MYMD Income Statement

2024-03-31

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses	1,068,320	987,987
Research and Development Expenses	1,198,938	770,430
Stock Based Compensation	517,365	69,068
Warrant Issuance Expenses		762,834
Loss from Operations	(2,784,623)	(2,590,319)
Other (Income) Expenses
Interest and Dividend Income	(18,306)	(25,824)
Gain/Loss on Sale of Investments	(175)	(175)
FMV Change - Equity Investments	899	1,712
FMV Change - Derivatives	(61,000)	120,700
FMV Change - Warrants	7,094,000	(1,175,000)
Total Other (Income) Expenses	7,015,418	(1,078,587)
Loss Before Income Tax	(9,800,041)	(1,511,732)
Income Tax Benefit
Net Loss	(9,800,041)	(1,511,732)
Preferred Stock Dividends	1,201,867	158,333
Net Loss Attributable to Common Stockholders	$ (11,001,908)	$ (1,670,065)
Net loss per common share - basic	$ (5.14)	$ (1.20)
Net loss per common share - diluted	$ (5.14)	$ (1.20)
Weighted average common shares outstanding - basic	2,141,131	1,392,210

MYMD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash	$ 225,655	$ 2,681,010
Marketable Securities	1,509,358	2,242,106
Prepaid expenses	725,159	893,226
Total Current Assets	2,460,172	5,816,342
Non-Current Assets
Lease Right-of-Use	34,904	47,389
Goodwill	10,498,539	10,498,539
Investment in Oravax Medical	1,500,000	1,500,000
Total Non-Current Assets	12,033,443	12,045,928
Total Assets	14,493,615	17,862,270
Current Liabilities
Trade and Other Payables	3,861,232	3,716,218
Lease Liability	35,981	48,870
Dividends Payable	45,828	265,019
Derivative Liability		61,000
Warrant Liability		867,000
Total Current Liabilities	3,973,023	4,988,089
Non-Current Liabilities
Deferred Compensation Payable, net of current	279,615	100,538
Total Non-Current Liabilities	279,615	100,538
Total Liabilities	4,252,638	5,088,627
Commitments and Contingencies
Mezzanine Equity
Series F Convertible Preferred Stock - Discount	(3,530,365)	(4,702,023)
Series F Convertible Preferred Stock - Derivative	(1,046,778)	(1,394,184)
Total Mezzanine Equity	303,385	404,071
SHAREHOLDERS’ EQUITY
Common Stock, par value $0.001, 16,666,666 shares authorized, 2,157,632 and 2,018,857 shares issued and outstanding as of March 31, 2024 and December 31, 2023	2,158	2,019
Additional Paid in Capital	122,769,885	114,200,096
Accumulated Deficit	(112,978,975)	(101,977,067)
Total Shareholders’ Equity	9,937,592	12,369,572
Total Liabilities and Shareholders’ Equity	14,493,615	17,862,270
Series F Convertible Preferred Stock [Member]
Mezzanine Equity
Series F Convertible Preferred Stock, 15,000 shares designated, par value $0,001 and a stated value of $1,000 per share, 4,988 and 6,633 shares issued and outstanding as of March 31, 2024 and December 31, 2023. Liquidation preference of $4,988,000 plus dividends at 10% per annum of $45,828 as of March 31, 2024	4,880,528	6,500,278
Series D Convertible Preferred Stock [Member]
SHAREHOLDERS’ EQUITY
Preferred Stock, value	144,524	144,524
Related Party [Member]
Current Liabilities
Due to MyMD FL Shareholders	$ 29,982	$ 29,982

About MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

WEBSITE	mymd.com
INDUSTRY	Biotechnology
EMPLOYEES	9

MyMD Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for MyMD Pharmaceuticals, Inc.? What does MYMD stand for in stocks?

MYMD is the stock ticker symbol of MyMD Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MyMD Pharmaceuticals, Inc. (MYMD)?

As of Fri May 17 2024, market cap of MyMD Pharmaceuticals, Inc. is 5.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MYMD stock?

You can check MYMD's fair value in chart for subscribers.

What is the fair value of MYMD stock?

You can check MYMD's fair value in chart for subscribers. The fair value of MyMD Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MyMD Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MYMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MyMD Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether MYMD is over valued or under valued. Whether MyMD Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact MyMD Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MYMD.

What is MyMD Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MYMD's PE ratio (Price to Earnings) is -0.4 and Price to Sales (PS) ratio is 3.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MYMD PE ratio will change depending on the future growth rate expectations of investors.